Skip to main content

Krishnansu S Tewari MD

Dr Krishnansu S Tewari MD, is a Professor and Director of Research in the Division of Gynecologic Oncology at the University of California, Irvine. He received his Bachelor's Degree in Molecular Biology at the University of California, Berkeley and went to medical school, residency in Ob/Gyn, and fellowship in Gynecologic Oncology at the University of California, Irvine. He serves as the Principal Investigator of the National Cancer Institute’s NRG-Oncology Cooperative Group and Gynecologic Oncology Group Partners at the University of California, Irvine. At UC Irvine, Dr Tewari is the Director of the Women's Disease Oriented Team for the Chao Family National Cancer Institute Designated Comprehensive Cancer Center. He is also the Director of the Gynecologic Oncology Program at St Joseph's Center for Cancer Prevention and Treatment. Dr Tewari is a voting member of the NRG’s Cervix Committee, Publications Committee, and Committee on Experimental Medicine, and Chairs the Society of Gynecologic Oncology’s (SGO) Publications Committee. In January 2016, Dr Tewari was appointed Member-At-Large to the SGO’s Nominating Committee.

Dr Tewari has published over 130 peer reviewed articles and written numerous book chapters. His research interests include novel targeted therapeutics in ovarian cancer and cervical cancer. Dr Tewari is funded by the National Institutes of Health to study surrogate markers of angiogenesis in cervical cancer and is the Study Chair/Principal Investigator for Gynecologic Oncology Group protocol 240 (GOG 240), the practice-changing phase III randomized clinical trial which demonstrated that compared to chemotherapy alone, the addition of the anti-angiogenesis drug, bevacizumab, significantly improved overall survival, progression-free survival, and response rate without a significant deterioration in health-related quality of life (Tewari et al, N Engl J Med 2014).  This pivotal clinical trial led directly to US FDA approval of bevacizumab for advanced cervical cancer on August 14, 2014. Following this regulatory milestone, based on GOG 240, bevacizumab was also approved by the European Medicines Agency for the European Union. Dr Tewari has been listed for nine consecutive years as one of the Top Doctors in Orange County and has been listed in Best Doctors of America for the past 5 years. An expert in robotic surgery, for the past 5 years Dr Tewari has been travelling annually to conduct robotic surgery workshops in different cities of India for women diagnosed with early stage cervical and endometrial cancer.

Latest contributions from Krishnansu S Tewari

26-01-2018 | Krishnansu S Tewari | Article

Advisory board comment

Comment on: Hyperthermic intraperitoneal chemotherapy boosts advanced ovarian cancer outcome

12-09-2017 | Cervical cancer | Podcast | Audio

Bevacizumab in cervical cancer

The phase III GOG 240 trial evaluated bevacizumab in women with advanced cervical cancer - Advisory Board member and lead investigator Krishnansu Tewari outlines the results of the final analysis in this podcast.